BioScrip (BIOS) Earns News Sentiment Rating of 0.06
Press coverage about BioScrip (NASDAQ:BIOS) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioScrip earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.4984730556886 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- MARVELL TECHNOLOGY GROUP LTD. (NASDAQ:MRVL) Files An 8-K Other Events (4-traders.com)
- Quick notice on Oversold Stock: BioScrip, Inc. (BIOS) stock Upward Move Ahead – Voice Of Analysts (analystsbuzz.com)
- BioScrip, Inc. (BIOS) Stock Price trades 16.71% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Anaren Subsidiary Unicircuit, Inc Receives $7.8 Million Order In Support of Airborne Radar Application (4-traders.com)
- $203.04 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter (americanbankingnews.com)
BioScrip (NASDAQ:BIOS) traded up 2.98% during trading on Friday, reaching $2.42. 750,127 shares of the company’s stock traded hands. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43. The firm’s market capitalization is $308.49 million. The firm has a 50 day moving average of $2.86 and a 200 day moving average of $2.29.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $218.11 million for the quarter, compared to analyst estimates of $220.05 million. BioScrip’s quarterly revenue was down 6.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.14) EPS. Equities analysts forecast that BioScrip will post ($0.55) EPS for the current year.
Several brokerages recently issued reports on BIOS. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Zacks Investment Research lowered shares of BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. SunTrust Banks, Inc. upgraded shares of BioScrip from a “hold” rating to a “buy” rating and boosted their target price for the company from $3.25 to $3.75 in a report on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. BioScrip has an average rating of “Hold” and an average target price of $3.75.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/24/bioscrip-bios-earns-news-sentiment-rating-of-0-06.html.
In other news, Director Michael G. Bronfein sold 27,000 shares of BioScrip stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the sale, the director now directly owns 129,669 shares in the company, valued at $348,809.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Coliseum Capital Management, L sold 2,846,941 shares of BioScrip stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $2.93, for a total transaction of $8,341,537.13. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,760,419 shares of company stock valued at $11,144,519. Insiders own 0.80% of the company’s stock.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.